KIT and mastocytoma: In many gastrointestinal stromal tumors (GISTs) (~85%) and mastocytomas, Kit has gain-of-function mutations, causing ligand-independent auto-activation of the receptor11, 12, 13, 14 (Supplementary Figure S1a).